Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Glaucoma supplement trial halted early – no clear results

NCT ID NCT04784234

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a daily dietary supplement called GlaucoCetin could improve vision in people with open-angle glaucoma who already had some vision loss. Only 12 participants were enrolled before the trial was terminated early. The supplement contained a mix of ingredients thought to protect optic nerve cells, but because the study stopped, we don't have reliable data on whether it helped.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GlaucoCetin (a dietary supplement containing curcumin, N-acetyl cysteine, ginkgo biloba, alpha-lipoic acid, citicoline, grape seed extract, green tea extract, coenzyme Q10, and other ingredients)
What this could lead to
If it had worked, GlaucoCetin might have pointed toward a way to slow vision loss in glaucoma by protecting optic nerve cells.
What could go wrong
The trial was terminated early with only 12 participants, so no reliable conclusions can be drawn. Dietary supplements often fail to show clear benefits in rigorous studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

12 people

The number who actually took part.

Started

Feb 2021

Finished

Oct 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age of 40 to 80 years * Bilateral open angle glaucoma with reliable visual field defects (at least one eye with mean deviation (MD) between -4.00 to -10.00 decibels (dB) on Humphrey Visual Field 24-2. * Group 1 (Peripheral): meets 1 hodapp-parrish-anderson (HPA) criteria for defect (3 contiguous points depressed on the pattern standard deviation (PSD) p \<5%, one of which is depressed at p \<1% level), and does not meet below paracentral criteria for Group 2. * Group 2 (Central): at least 1 paracentral point repeatedly depressed at p\<1% on 24-2. Also meets the HAP criteria outlined above. * Visual acuity 20/40 or better in each eye * Intraocular Pressure (IOP) controlled at 2 measurements \>3 months * Clear media Exclusion Criteria: * Known bleeding disorder * History of epilepsy or on anti-seizure medication * Uncontrolled hypertension or diabetes * Uncontrolled IOP * Eye pathology leading to inaccurate IOP measurement * Visually significant retinal pathology affecting vision in past or active (such as diabetic retinopathy or age related macular degeneration) * Non-glaucomatous optic neuropathy * Visually significant cataract (worse then 2+ cataract, or what is determined visually clinically significant by physician) * History of ocular trauma * Selective laser trabeculoplasty or laser procedure within past 3 months * Cataract surgery within past 3 months * Incisional glaucoma surgery within 6 months * Current use of nitroglycerin * Current use of antiplatelet therapy besides aspirin (such as clopidogrel) or anticoagulation (such as warfarin) * Current use of systemic steroids or immunomodulating agents such as methotrexate. * Sensitivity or allergy to any ingredients in GlaucoCetin: Curcumin, L-Taurine, N-Acetyl Cysteine, Niacinamide, Ginkgo Biloba, Lipoic Acid, Citicoline, Grape Seed Extract, Green Tea Leaf Extract, Coenzyme Q10, Biotin, Natural Astaxanthin, flavonoid complex containing Fisetin, Quercetin, and Luteolin * Recent change in systemic medications or vitamins * Use of Biotin, Ginkgo Biloba, Citicoline within past 3 months (or any other Glaucocetin ingredients within 1 month) * Unreliable visual fields * Unwilling to take supplement or placebo for 6 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary open-angle glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Wills Eye Hospital, Glaucoma Research Center

    Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.